Page last updated: 2024-12-05

ketotifen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ketotifen is a mast cell stabilizer, antihistamine, and anti-inflammatory drug. It is primarily used for the treatment of allergic conditions, including allergic rhinitis, allergic conjunctivitis, and chronic urticaria. Ketotifen exerts its effects by inhibiting the release of histamine and other inflammatory mediators from mast cells. It is thought to work by stabilizing the mast cell membrane, preventing the release of these mediators. Ketotifen has been studied for its potential use in the treatment of asthma, atopic dermatitis, and other allergic disorders. It is available in both oral and topical formulations. The synthesis of ketotifen involves several steps, including the reaction of a dihydropyran derivative with a cyanoacetic acid ester. The resulting compound is then converted to ketotifen through a series of reactions.'

Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3827
CHEMBL ID534
CHEBI ID92511
SCHEMBL ID4436
MeSH IDM0012002

Synonyms (154)

Synonym
MLS002222254 ,
BIDD:GT0509
smr001307257
AC-15945
ketotifin
AB00053575-21
BRD-K28936863-051-05-8
10h-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-
4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one
DIVK1C_000111
KBIO1_000111
zaditor
4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10h-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
SPECTRUM_000426
BPBIO1_000575
10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-
ketotifene
ketotifen [inn:ban]
ketotifenum [inn-latin]
einecs 252-099-7
hc 20-511
ketotifeno [inn-spanish]
ketotiphen
ketotifene [inn-french]
ketotiphene
brn 3983897
4,9-dihydro-4-(1-methyl-4-piperidylidene)-10h-benzo(4,5)-cyclohepta(1,2-b)thiophen-10-one
hsdb 7283
NCGC00015580-01
tocris-0784
NCGC00015580-02
NCGC00022572-02
lopac-k-2628
cas-34580-14-8
LOPAC0_000706
PRESTWICK3_000371
IDI1_000111
SPECTRUM5_001395
OPREA1_335550
BSPBIO_002964
AB00053575
10h-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (2e)-2-butenedioate (1:1)
ketotifen
34580-13-7
10-(1-methyl-4-piperidylidene)-5h-benzo[[?]:[?]]cyclohepta[[?]]thiophen-4-one
4-(1-methyl-4-piperidylidene)-9-hydrobenzo[a]thiopheno[3,2-d][7]annulen-10-one
4-(1-methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one
DB00920
OPREA1_553550
NCGC00022572-05
KBIO2_000906
KBIO2_003474
KBIO3_002184
KBIO2_006042
KBIOGR_001289
KBIOSS_000906
PRESTWICK0_000371
SPBIO_002442
SPECTRUM3_001382
NINDS_000111
SPECTRUM2_001198
SPBIO_001275
SPECTRUM4_000805
PRESTWICK1_000371
PRESTWICK2_000371
BSPBIO_000521
NCGC00022572-04
NCGC00015580-03
STK048448
HMS2090F16
NCGC00015580-09
L000753
CHEMBL534 ,
(r)-ketotifen
alaway (tn)
ketotifen (inn)
D08105
AKOS000541268
4-(1-methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one(ketotifen)
bdbm50002087
4-(1-methyl-piperidin-4-ylidene)-4,9-dihydro-1-thia-benzo[f]azulen-10-one(ketotifen hydrogen malate)
NCGC00015580-08
SR-01000000175-7
sr-01000000175
dtxsid7023190 ,
dtxcid203190
tox21_110176
cas-34580-13-7
CCG-204791
NCGC00015580-05
NCGC00015580-07
NCGC00015580-04
NCGC00015580-06
NCGC00015580-11
NCGC00015580-10
unii-x49220t18g
ketotifenum
x49220t18g ,
ketotifeno
ketotifene fumarate
4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
(z)-2-butenedioate;10-(1-methyl-4-piperidinylidene)-5h-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one
bdbm94597
(z)-but-2-enedioate;10-(1-methylpiperidin-4-ylidene)-5h-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one
us9333199, ketotifen
us9138431, ketotifen
cid_5282408
10-(1-methyl-4-piperidylidene)-5h-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one;maleate
cid_45479747
ketotifen hydrogen fumarate impurity e [ep impurity]
ketotifen [vandf]
ketotifen [inn]
ketotifen [hsdb]
ketotifen [mi]
ketotifen [who-dd]
hc-20511
10-(1-methylpiperidin-4-ylidene)-5h-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one
gtpl7206
SCHEMBL4436
NCGC00015580-13
tox21_110176_1
4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9h)-one
4,9-dihydro-4-(1-methyl-4-piperidylidene)-10h-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
4-(1-methyl-4-piperidinylidene)-4,9-dihydro-10h-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one #
AB00053575_23
AB00053575_22
2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),4,11,13-pentaen-8-one
hc 20511 fumarate
CHEBI:92511 ,
10-(1-methyl-4-piperidinylidene)-5h-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one
SBI-0050684.P004
Q2458673
BRD-K28936863-051-18-1
SDCCGSBI-0050684.P005
NCGC00015580-23
2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
A918910
(-)-ketotifen
DTXSID701019837
116655-76-6
2-(1-methylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),4,11,13-pentaen-8-one
EN300-18530986
CS-0013637
HY-B0157
4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo
10-(1-methyl-4-piperidinylidene)-5h-benzo(1,2)cyclohepta(3,4-b)thiophen-4-one
ketotifene (inn-french)
ketotifenum (inn-latin)
ketotifeno (inn-spanish)
4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10h-benzo(4,5)cyclohepta(1,2-b)-thiopen-10-one
s01gx08
4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10h-benzo(4,5)cyclohepta(1,2-b)thiophen-10-one
r06ax17
GLXC-25233

Research Excerpts

Overview

Ketotifen is a second-generation noncompetitive H1-antihistamine and mast-cell stabilizer. It is a mast cell stabilizer and useful in younger children with allergic diseases such as asthma and allergic rhinitis.

ExcerptReferenceRelevance
"Ketotifen is a second-generation noncompetitive H1-antihistamine and mast-cell stabilizer. "( In vitro safety of ketotifen as a topical nasal rinse.
Adappa, ND; Bosso, JV; Cohen, NA; Kennedy, DW; Kohanski, MA; Maina, IW; Palmer, JN; Papagiannopoulos, P; Patel, NN; Tong, CCL; Triantafillou, V, 2020
)
2.33
"Ketotifen is a H1 receptor antagonist and montelukast is a leukotriene receptor antagonist."( Comparison of the efficacy of KOB03, ketotifen, and montelukast in an experimental mouse model of allergic rhinitis.
Jung, HW; Jung, JK; Park, YK, 2013
)
1.38
"Ketotifen is a second generation H₁ histamine receptor antagonist which is more permeable to the brain than newer H₁ histamine receptor antagonists."( First and second generation H₁ histamine receptor antagonists produce different sleep-inducing profiles in rats.
Honda, K; Ikeda, M; Ikeda-Sagara, M; Mohammad, S; Ozaki, T; Tsuno, S; Unno, K, 2012
)
1.1
"Ketotifen fumarate is a topical antiallergic combination mast-cell stabilizer and antihistamine indicated for the temporary prevention of ocular itching due to allergic conjunctivitis. "( Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo
Crampton, HJ, 2003
)
2.12
"Ketotifen is an antiallergic drug and may have direct inhibitory effects on eosinophils. "( Effect of ketotifen on the production of reactive oxygen species from human eosinophils primed by eotaxin.
Adachi, T; Chihara, J; Cui, CH; Hamada, K; Kanda, A; Kayaba, H; Oyamada, H; Saito, N; Sannohe, S; Ueki, S; Yamada, Y; Yamaguchi, K, 2003
)
2.16
"Ketotifen is an antihistamine which may be used to treat asthma. "( Ketotifen alone or as additional medication for long-term control of asthma and wheeze in children.
Bassler, D; Ducharme, FM; Forster, J; Mitra, A; Schwarzer, G, 2004
)
3.21
"Ketotifen is a mast cell stabilizer and useful in younger children with allergic diseases such as asthma and allergic rhinitis. "( Suppressive effects of ketotifen on Th1- and Th2-related chemokines of monocytes.
Chang, HC; Chen, CN; Chiang, W; Hua, YM; Hung, CH; Jong, YJ; Suen, JL, 2007
)
2.09
"3. Ketotifen is a beneficial substance for long-term treatment of bronchial asthma."( [Long-term therapy of bronchial asthma with ketotifen. European experiences].
Magnussen, H, 1980
)
1.04
"Ketotifen is a compound with strong anti-anaphylactic and anti-histaminic properties both in experimental mental animals and man. "( Dissociation between the anti-anaphylactic and the anti-histaminic actions of ketotifen.
Baggiolini, M; Martin, U, 1981
)
1.93
"Ketotifen is a cycloheptathiophene with experimental antihistaminic, anti-allergic and anti-anaphylactic effects equal or superior to those of DSCG."( A double-blind comparison of ketotifen and disodium cromoglycate in atopic adult asthmatics.
Sears, MR, 1983
)
1.28
"Ketotifen is a new chemical entity which has been shown pharmacologically to be both an anti-histamine and an anti-allergic agent. "( The orally administered anti-allergic agent, ketotifen; efficacy in atopic and non-atopic bronchial asthma.
Bernath, Z; Carrasco, E; Galleguillos, F,
)
1.83
"Ketotifene is a new preventive treatment for asthma possessing the main advantage of being administered orally. "( [Preventive treatment of asthma with ketotifen : an analysis of 1 791 cases treated in general practice].
Bourdain, M; Gence, B; Lebeau, B; Loria, Y,
)
1.85
"Ketotifen is an anti-H-1 antihistamine with MC-stabilizing properties."( Ketotifen therapy in chronic graft-versus-host disease (cGVHD): effect on mast cells and fibroblasts.
Levi-Schaffer, F; Nagler, A; Segal, V; Slavin, S, 1995
)
2.46
"Ketotifen is an anti-allergic agent that was recently shown to prevent experimental gastric and colonic mucosal injury. "( Ketotifen is protective against indomethacin-induced intestinal ulceration in the rat.
Dinari, G; Karmeli, F; Marcus, H; Weizen, T; Zahavi, I, 1996
)
3.18
"Ketotifen is a tricyclic drug with a wide spectrum of pharmacological effects. "( The actions of ketotifen on intestinal smooth muscles.
Abu-Dalu, R; Hanani, M; Zhang, JM, 1996
)
2.09
"Ketotifen is a sedative antihistamine promoted heavily for asthma treatment. "( [Ketotifen (Zaditen and K-Asthmal): a drug with sales disproportionate to its demonstrated effectiveness].
Pérez-Padilla, JR,
)
2.48
"Ketotifen is an older molecule that possesses antihistaminic activity and is reported to have additional pharmacological properties."( A comparison of the effects of olopatadine and ketotifen on model membranes.
Brockman, H; Graff, G; Spellman, J; Yanni, J, 2000
)
1.29
"Ketotifen (Zaditen) is a widely used prophylactic antiasthmatic drug with pronounced antianaphylactic properties and a specific H1-antihistaminic effect. "( Acute ketotifen overdosage. A review of present clinical experience.
Donatini, B; Hall, M; Krupp, P; Le Blaye, I,
)
2.05
"Ketotifen is a very useful drug for prevention of asthma in children with atopic dermatitis and total IgE more than 50 IU/mL."( Prevention of asthma by ketotifen in infants with atopic dermatitis.
Baba, M; Iikura, Y; Mikawa, H; Naspitz, CK; Nishima, S; Sole, D; Talaricoficho, S, 1992
)
1.31
"Ketotifen is an orally active prophylactic agent for the management of bronchial asthma and allergic disorders. "( Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.
Fitton, A; Goa, KL; Grant, SM; Sorkin, EM, 1990
)
3.16
"Ketotifen is a derivative of the cyclohepatotifen which has shown to have an antianaphylactic effect which inhibits chemical mediator release in mast cells and basophils."( [Ketotifen in the prophylaxis of infantile asthma. Controlled clinical trials].
Huerta López, JG,
)
1.76
"Ketotifen (Zaditen) is a new, orally active benzocycloheptathiophene derivative for use in the prophylaxis of asthma. "( Determination of the central effects of the asthma prophylactic ketotifen, the bronchodilator theophylline, and both in combination: an application of quantitative electroencephalography to the study of drug interactions.
Abt, K; Irwin, P; Matejcek, M; Neff, G; Wehrli, W, 1985
)
1.95

Effects

Ketotifen has a favorable safety and tolerability profile, which may have a positive impact on compliance. It has a good suppressing effect on weals and pruritus.

Ketotifen has been shown to be a potent anti-histamine but there is no evidence from these in vivo studies to suggest that it has any additional inhibitory activity on release of mediators from mast cells in human skin. The drug has been reported to help induce remission in some patients with idiopathic anaphylaxis and has steroid sparing effects in other patients.

ExcerptReferenceRelevance
"Ketotifen has a favorable safety and tolerability profile, which may have a positive impact on compliance, an important aspect of effective symptomatic control of allergic conjunctivitis."( Ocular tolerability and safety of ketotifen fumarate ophthalmic solution.
Abelson, MB; Chapin, MJ; Kapik, BM; Shams, NB,
)
1.13
"Ketotifen has a good suppressing effect on weals and pruritus."( [Ketotifen treatment of chronic urticaria. An open study of therapeutically difficult courses].
Lässig, W; Taube, KM; Wozniak, KD, 1985
)
1.9
"Ketotifen has recently been reported to inhibit the growth of both asexual and sexual malaria parasites. "( Human dihydrofolate reductase influences the sensitivity of the malaria parasite Plasmodium falciparum to ketotifen - A cautionary tale in screening transgenic parasites.
Kirk, K; Maier, AG; Ridgway, MC; Saliba, KJ; Tate, CJ; Tran, PN, 2016
)
2.09
"Ketotifen has a favorable safety and tolerability profile, which may have a positive impact on compliance, an important aspect of effective symptomatic control of allergic conjunctivitis."( Ocular tolerability and safety of ketotifen fumarate ophthalmic solution.
Abelson, MB; Chapin, MJ; Kapik, BM; Shams, NB,
)
1.13
"Ketotifen has been shown to be a potent anti-histamine but there is no evidence from these in vivo studies to suggest that it has any additional inhibitory activity on release of mediators from mast cells in human skin."( A comparison of the in vivo effects of ketotifen, clemastine, chlorpheniramine and sodium cromoglycate on histamine and allergen induced weals in human skin.
Davies, RJ; Meyrick Thomas, RH; Moodley, I; Phillips, MJ, 1983
)
1.26
"Ketotifen fumarate has been demonstrated to inhibit the noncholinergic contraction in guinea pig airways in vitro, but no attempt has been made to identify the receptor type."( Ketotifen modulates noncholinergic contraction in guinea pig airways in vitro by a prejunctional nonhistamine receptor.
Demedts, MM; Pype, JL; Verleden, GM, 1994
)
2.45
"Ketotifen has been reported to help induce remission in some patients with idiopathic anaphylaxis and has steroid sparing effects in other patients with idiopathic anaphylaxis."( Malignant and corticosteroid-dependent idiopathic anaphylaxis: successful responses to ketotifen.
Choy, AC; Fitzsimons, EJ; Harris, KE; Patterson, R, 1997
)
1.24
"Ketotifen also has pronounced antihistaminic and antianaphylactic properties which result in moderate to marked symptom improvement in the majority of patients with atopic dermatitis, seasonal or perennial rhinitis, allergic conjunctivitis, chronic or acute urticaria or food allergy."( Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders.
Fitton, A; Goa, KL; Grant, SM; Sorkin, EM, 1990
)
2.44
"Ketotifen has a good suppressing effect on weals and pruritus."( [Ketotifen treatment of chronic urticaria. An open study of therapeutically difficult courses].
Lässig, W; Taube, KM; Wozniak, KD, 1985
)
1.9

Actions

ExcerptReferenceRelevance
"Ketotifen did not produce any influence on histamine release provoked by the cytotoxic secretion activators, chlorpromazine and mellitin."( [Characteristics of the effect of ketotifen on the selective and non-selective histamine release from human basophils].
Gushchin, IS; Zebrev, AI, 1984
)
1.27

Treatment

Ketotifen pretreatment inhibited toxin A-associated intestinal secretion by 42.5% and mannitol permeability by 56.3% and reduced epithelial cell inflammation and necrosis. Treatment was associated with reversal of the histopathology and enzyme changes in every case.

ExcerptReferenceRelevance
"The ketotifen-pretreated group was administered orally with ketotifen before NDV infection."( Evidence for a role of mast cells in the mucosal injury induced by Newcastle disease virus.
Ding, Y; Han, D; Li, R; Li, W; She, R; Sun, Q; Wang, D; Yue, Z, 2009
)
0.83
"Ketotifen treatment provided significant relief of symptoms. "( Levothyroxine versus ketotifen in the treatment of patients with chronic urticaria and thyroid autoimmunity.
Akar, A; Calişkaner, Z; Karaayvaz, M; Ozangüç, N; Oztürk, S; Turan, M, 2002
)
2.08
"Ketotifen treatment does not appear to prohibit or reverse the inflammatory process in the gastric mucosa in EGE, although long-term effects of steroids may be avoided."( Longstanding eosinophilic gastroenteritis of more than 20 years.
Freeman, HJ, 2009
)
1.07
"Ketotifen fumarate treatment significantly reduced the total symptoms and signs score for each patient as well as each symptoms and signs at all time points compared with day 0 (p < 0.0001 and p < 0.016, respectively). "( The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.
Baena-Cagnani, CE; Berra, A; Gagliardi, J; Gallino, N; Gomez Demel, E; Mariani, AL; Martín, AP; Serra, HM; Urrets-Zavalia, E; Urrets-Zavalia, J, 2003
)
2.12
"Ketotifen-treated eyes experienced significantly less ocular itching induced by CAC than nedocromil-treated eyes and those that received placebo at both the 5-minute and 12-hour posttreatment allergen challenges (all P < 0.05)."( A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
Greiner, JV; Minno, G, 2003
)
1.32
"The ketotifen treatment administered on the infected mice differently blocked the immune response against E."( Immune response and inhibitory effect of ketotifen on the BALB/c and C3H/HeN mice infected with Echinostoma hortense.
Kim, IS; Kim, JB; Kim, JL; Lee, KJ; Ryang, YS; Sung, HJ; Yang, EJ, 2007
)
1.09
"Ketotifen treatment significantly reduced the first phase of contraction in red Duroc wounds to a level equivalent to Yorkshire wounds, but had no detectable effect on the postepithelialization phase of contraction."( The mast cell stabilizer ketotifen prevents development of excessive skin wound contraction and fibrosis in red Duroc pigs.
Gallant-Behm, CL; Hart, DA; Hildebrand, KA,
)
1.16
"Ketotifen pretreatment significantly decreased the macroscopic damage and the increase in colonic weight."( Ketotifen ameliorates capsaicin-augmented acetic acid-induced colitis.
Eliakim, R; Karmeli, F; Okon, E; Rachmilewitz, D, 1995
)
2.46
"Ketotifen treatment was very effective."( Diffuse erythrodermic cutaneous mastocytosis with bone marrow infiltration.
Cevik, N; Irken, G; Olgun, N; Oren, B; Oren, H; Polat, M, 1993
)
1.01
"Ketotifen pretreatment inhibited toxin A-associated intestinal secretion by 42.5% and mannitol permeability by 56.3% and reduced epithelial cell inflammation and necrosis. "( Ketotifen inhibits Clostridium difficile toxin A-induced enteritis in rat ileum.
Castagliuolo, I; Eliakim, R; Joshi, MA; Karmeli, F; Kelly, CP; LaMont, JT; O'Keane, CJ; Pothoulakis, C; Rachmilewitz, D, 1993
)
3.17
"In ketotifen-treated infected rats, the increase of MPO at day 12 was less pronounced, but MPO activity remained elevated and mast cell numbers were increased at day 35."( Development and sequels of intestinal inflammation in nematode-infected rats: role of mast cells and capsaicin-sensitive afferents.
Bueno, L; Fioramonti, J; Garcia-Villar, R; Gay, J, 2000
)
0.82
"Ketotifen treatment significantly reduced cerulein induced edema (1.30+/-0.21 vs 0.70+/-0.15; p<0.001), neutrophil infiltration (1.50+/-0.16 vs 0.60+/-0.16; p<0.001) and attenuated the increase in amylase (4394.0+/-149.5 U/L vs 3350.5+/-216.9 U/L; p<0.05) and MPO activity (1.14+/-0.13 U/gr tissue vs 0.54+/-0.08 U/gr tissue; p<0.001)."( Effects of mast-cell stabilization in cerulein-induced acute pancreatitis in rats.
Celik, HA; Oruç, N; Ozütemiz, AO; Yönetçi, N; Yüce, G, 2001
)
1.03
"Ketotifen treatment may reduce the severity of AP in rats."( Effects of mast-cell stabilization in cerulein-induced acute pancreatitis in rats.
Celik, HA; Oruç, N; Ozütemiz, AO; Yönetçi, N; Yüce, G, 2001
)
1.03
"Ketotifen treatment was associated with reversal of the histopathology and enzyme changes in every case."( The histological and histochemical effects of ketotifen in allergic rhinitis.
Ibrahim, TE; Inaam, PK; Mohammed, MH; Talaat, MA, 1991
)
1.26
"Ketotifen treatment together with a desensitization."( [Role of ketotifen in the immunotherapy of atopic asthmatics].
Haddad, G; Pacaud, D; Papeix, P; Steeg, LF; Tran, Q; Vincent, J, 1986
)
1.41
"S). Treatments by Ketotifen and Cromolyn Sodium similarly markedly alleviated IIR-mediated liver injury as confirmed by significant reduction of the above biomedical changes whereas Compound 48/80 further aggravated IIR-mediated liver injury by dramatically enhancing the above biomedical changes."( Effects of anti-histamine treatment on liver injury triggered by small intestinal ischemia reperfusion in rats.
Gan, XL; Hei, ZQ; Huang, PJ; Liu, DZ; Liu, JP; Wang, YL, 2014
)
0.73
"Treatment with Ketotifen and CS increased the survival rate compared with group M (P < 0.05), attenuated the down-regulation or up-regulation of the above index (P < 0.05)."( Influence of Ketotifen, Cromolyn Sodium, and Compound 48/80 on the survival rates after intestinal ischemia reperfusion injury in rats.
Gan, XL; Gao, WL; Hei, ZQ; Huang, PJ; Shen, N; Wei, J, 2008
)
1.05
"Pre-treatment with ketotifen abrogated these responses (p=0.0004, 0.005, respectively)."( Zebrafish mast cells possess an FcɛRI-like receptor and participate in innate and adaptive immune responses.
Berman, JN; Da'as, S; Dobson, JT; Lin, TJ; Marshall, JS; McBride, ER; Nasrallah, GK; Neuberg, DS; Teh, EM; Wang, H, 2011
)
0.69
"Treatment with ketotifen decreased tissue hydroxyproline levels, histological damage, and the stenosis index."( Ketotifen ameliorates development of fibrosis in alkali burns of the esophagus.
Karaoglu, AO; Ozutemiz, O; Tuncyurek, M; Yenisey, C; Yukselen, V, 2004
)
2.11
"Pretreatment with ketotifen, a histamine H1 receptor antagonist, and capsaicin inhibited LPA-induced ISRs."( Itch-scratch responses induced by lysophosphatidic acid in mice.
Hashimoto, T; Momose, K; Ohata, H, 2004
)
0.65
"Pretreatment with ketotifen significantly increased the duration of pregnancy in sensitized animals, compared with untreated animals."( Induction of premature labor and delivery by allergic reaction and prevention by histamine H1 receptor antagonist.
Bytautiene, E; El-Zeky, F; Garfield, RE; Romero, R; Saade, GR; Vedernikov, YP, 2004
)
0.65
"The treatment with ketotifen prevented hypermotility and mast cell hyperplasia and diminished mucosal mast cell activity."( Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat.
Porras, M; Serna, H; Vergara, P, 2006
)
0.97
"Pretreatment with ketotifen, a mast cell stabilizer (1 mg/kg) protected rat gastric mucosa from the amplified injury induced by capsaicin and ethanol."( Ketotifen and nitroxides decrease capsaicin-augmented ethanol-induced gastric damage in rats.
Eliakim, R; Karmeli, F; Okon, E; Rachmilewitz, D, 1995
)
2.06
"Pretreatment with ketotifen, a connective tissue mast cell stabilizer, prevented the formation of gastric mucosal lesions, the increases of gastric mucosal lipid peroxide content, xanthine oxidase and myeloperoxidase activities, and serum serotonin level; and the decreases of gastric mucosal nonprotein SH content, glutathione peroxidase activity, and blood flow found at 0.5 hr after compound 48/80 treatment."( Relationship between changes of active oxygen metabolism and blood flow and formation, progression, and recovery of lesions is gastric mucosa of rats with a single treatment of compound 48/80, a mast cell degranulator.
Ishiguro, I; Kobayashi, T; Nishida, K; Ohta, Y, 1997
)
0.62
"Pretreatment with ketotifen at an oral dose of 1 mg kg-1 inhibited mast cell degranulation in responses to either L-NAME or MB."( Mast cell degranulation in rat mesenteric venule: effects of L-NAME, methylene blue and ketotifen.
Bandoh, T; Hayashi, S; Kimura, M; Mitani, H; Totsuka, T, 1999
)
0.85
"Pretreatment with ketotifen or pyrilamine, followed by ethanol, caused no change in macromolecular leakage compared with controls. "( Mast cell stabilization prevents ethanol-induced rat gastric mucosal injury: mechanisms of protection.
Bardhan, KD; Brown, NJ; Jacob, S; Kalia, N; Reed, MW, 2000
)
0.64
"Oral treatment with ketotifen, an inhibitor of mast cell degranulation, at a dose comparable to that recommended for man, was associated with a decrease in both mast cell degranulation and in skin fibrosis, suggesting the potential for its use in human scleroderma."( Ketotifen prevents skin fibrosis in the tight skin mouse.
Harley, R; LeRoy, EC; Walker, M, 1990
)
2.04
"Treatment with ketotifen prevented the induction of further beta-adrenergic tachyphylaxis."( The effect of ketotifen on bronchial beta-adrenergic tachyphylaxis in normal human volunteers.
Pauwels, R; Van der Straeten, M, 1988
)
0.98
"Treatment with ketotifen afforded a decrease, although insignificant, in the number of coughing attacks, a significant decrease in the number of episodes of dyspnoea (p less than 0.025) and a significant decrease in the number of episodes of airway obstruction (p less than 0.0005)."( Wheezy bronchitis: results of treatment with ketotifen.
Cserháti, EF; Gegesi Kiss, A; Kelemen, J; Mezel, G; Puskás, J,
)
0.73

Toxicity

Ketotifen fumarate 0.1% showed less toxic effects on human corneal epithelial cells compared to ketotifens fumarine 0.2%. The principle side effect of kettifen therapy observed in this age group was weight gain.

ExcerptReferenceRelevance
"A double-masked study was performed to investigate a possible side effect of the antiallergic substance Picumast dihydrochloride on lens transparency."( Lens safety study with Picumast dihydrochloride--a double masked study using the Scheimpflug method.
Goder, G; Hockwin, O; Laser, H; Meinel, U; Messinger, D; Müller-Breitenkamp, U, 1990
)
0.28
" On the contrary, when given simultaneously, the antiallergic drug increased the toxic effect of adriamycin."( Effect of ketotifen on adriamycin toxicity: role of histamine.
Baldini, L; Bartoli Klugman, F; Candussio, L; Decorti, G; Grill, V; Mallardi, F; Zweyer, M, 1988
)
0.68
" The principle side effect of ketotifen therapy observed in this age group was weight gain."( Efficacy and safety of ketotifen in young children with asthma.
Cumella, JC; Jaber, L; Varsano, I; Volovitz, B, 1988
)
0.87
" Ketotifen was safe and well tolerated in the adult and pediatric populations, with an incidence of ocular adverse events of 18."( Ocular tolerability and safety of ketotifen fumarate ophthalmic solution.
Abelson, MB; Chapin, MJ; Kapik, BM; Shams, NB,
)
1.32
" The type and frequency of adverse events were similar across treatment groups."( Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis.
Cooper, C; Kidd, M; Lanz, R; McKenzie, SH; Steven, I, 2003
)
0.63
" There were no significant differences in adverse events between groups."( Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
Abelson, MB; Casey, R; Dubiner, H; Greiner, JV; Kapik, BM; Lonsdale, J; Mundorf, T; Parver, L; Shams, NB, 2003
)
0.63
"025% eye drops were safe and statistically effective in preventing ocular itching, injection, and other signs and symptoms of allergic conjunctivitis at 15 minutes, 6 hours, and 8 hours after a single dose and at 8 hours after the final dose of a 4-week twice daily regimen."( Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
Abelson, MB; Casey, R; Dubiner, H; Greiner, JV; Kapik, BM; Lonsdale, J; Mundorf, T; Parver, L; Shams, NB, 2003
)
0.63
" Rhinitis symptoms score (parent-rated), clinical evaluation of symptoms (investigator-rated) and adverse event profiles during the treatment period."( Perennial rhinitis in the under 4s: a difficult problem to treat safely and effectively? A comparison of intranasal fluticasone propionate and ketotifen in the treatment of 2-4-year-old children with perennial rhinitis.
Fokkens, WJ; Scadding, GK, 2004
)
0.52
" No drug-related systemic adverse events were reported, and ocular adverse events were comparable to placebo."( Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
Abelson, MB; Crampton, HJ; Ferzola, NJ; McWhirter, CL, 2004
)
0.58
"When antiallergic agents are used to treat allergic conjunctivitis other than olopatadine, a particularly toxic effect on conjunctival cells associated with azelastine and ketotifen, rather than olopatadine, should be considered clinically."( Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
Kim, N; Lee, JE; Lee, JS; Oum, BS, 2008
)
0.54
" Second-generation antihistamines have become increasingly popular because of their comparable efficacy and lower incidence of adverse effects relative to their first-generation counterparts, and the safety and efficacy of this drug class are established in the adult population."( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Moeller, ML; Nahata, MC; Phan, H, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

Ketotifen rapidly absorbed from all dosage forms reaching Cmax in the order of 400 pg ml-1 after the syrup formulations. It is a commonly used prophylactic agent in various allergic disorders in adults and children.

ExcerptReferenceRelevance
"Published pharmacokinetic data on ketotifen are sparse, although it is a commonly used prophylactic agent in various allergic disorders in adults and children."( Ketotifen pharmacokinetics in children with atopic perennial asthma.
Ludden, TM; McFadyen, ML; Miller, R, 1997
)
2.02
" This quantitation method was successfully applied to a pharmacokinetic study of ketotifen and its major metabolite after oral administration of 2 mg ketotifen fumarate to 16 healthy volunteers."( Determination of ketotifen and its conjugated metabolite in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study.
Chen, X; Gu, J; Han, Y; Liu, D; Wang, Y; Zhong, D, 2003
)
0.88

Bioavailability

Ketotifen fumarate (KF) bioavailability is reported to be only ~ 50% due to hepatic first-pass metabolism. The results showed a dramatic increase in ketot ifen mean residence time (MRT) and bioavailability compared to topical drop therapy and drug soaked lenses.

ExcerptReferenceRelevance
" The syrup formulations showed a significantly more rapid rate of absorption as assessed by Tmax."( Pharmacokinetics of ketotifen after oral administration to healthy male subjects.
Beck, O; Dahlström, B; Eckernäs, SA; Grahnén, A; Lindström, B; Lönnebo, A, 1992
)
0.61
" The absolute bioavailability of KF after intranasal administration was 66%."( Pharmacokinetics of ketotifen fumarate after intravenous, intranasal, oral and rectal administration in rabbits.
Hamada, K; Sekikawa, H; Sudo, J; Taniuchi, Y; Yagi, N, 2002
)
0.64
" Selected compounds were further evaluated for their oral anti-histaminic activity in mice, bioavailability in rats, and their anti-inflammatory activity in mice OVA-induced biphasic cutaneous reaction model."( Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
Isobe, Y; Kubota, K; Kurebayashi, H; Miyachi, H; Onishi, M; Tobe, M, 2011
)
0.37
" The results showed a dramatic increase in ketotifen mean residence time (MRT) and bioavailability compared to topical drop therapy and drug soaked lenses."( Sustained in vivo release from imprinted therapeutic contact lenses.
Byrne, ME; McBride, MK; Paine, AC; Tieppo, A; Voyles, ML; White, CJ, 2012
)
0.64
" In both types of PSA, a constant absorption rate was maintained for up to 23 h after 7-h lag time."( In vivo enhancement of transdermal absorption of ketotifen by supersaturation generated by amorphous form of the drug.
Inoue, K; Sugibayashi, K, 2012
)
0.63
" Ketotifen fumarate (KF) bioavailability is reported to be only ~ 50% due to hepatic first-pass metabolism."( Novel delivery approach for ketotifen fumarate: dissofilms formulation using 3² experimental design: in vitro/in vivo evaluation.
Badr-Eldin, SM; Fahmy, RH, 2014
)
1.61
"Ketotifen an anti-allergic drug delivered via eye drops has major limitations, including poor ocular bioavailability and poor patient compliance."( Extended release of ketotifen from silica shell nanoparticle-laden hydrogel contact lenses: in vitro and in vivo evaluation.
Koli, AR; Mangukiya, MA; Maulvi, FA; Patel, PA; Ranch, KM; Shah, DO; Vaidya, RJ, 2016
)
2.2
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

An open study was carried out in 74 wheezy infants and children, average age 16 months, to assess the efficacy and tolerance of ketotifen given in the form of a syrup.

ExcerptRelevanceReference
"The pharmacokinetics of 2 mg ketotifen from four different oral dosage forms were examined in two randomized, balanced cross-over studies."( Pharmacokinetics of ketotifen after oral administration to healthy male subjects.
Beck, O; Dahlström, B; Eckernäs, SA; Grahnén, A; Lindström, B; Lönnebo, A, 1992
)
0.9
" Allergen (Southern Grass Mix) was administered intradermally 2 h after last drug dosage and the surface areas of the immediate wheal-and-flare-reactions were measured 15 min later."( Effect of enalapril on allergen-induced cutaneous hypersensitivity reaction.
Snyman, JR; Sommers, DK, 1991
)
0.28
" Following administration of a low dosage of ketotifen, the parasite first developed a multilamellate pellicular complex which resembled a medullary sheath and then developed vacuoles and cavitations."( Effect of ketotifen on the ultrastructure of the erythrocytic stages of Plasmodium yoelii.
Cao, HM; Pan, XQ, 1990
)
0.94
"17 children suffering from neurodermatitis, aged 2 to 14 years, were treated with ketotifen at a dosage of 1 mg twice daily."( Effectiveness of ketotifen in the treatment of neurodermatitis in childhood.
Kikindjanin, V; Stevanocvić, V; Vukaviíc, T, 1990
)
0.84
" In conclusion, 8 mg/day azelastine, in either a single or twice daily dosage regimen may be regarded as providing effective prophylaxis against bronchial asthma."( Azelastine in the prophylactic treatment of bronchial asthma: an Italian multicentre comparison with ketotifen.
Ambrosi, L; Bariffi, F; Carino, M; Catena, E; Ceccarelli, G; Ciampini, M; Condoluci, M; Crimi, N; Ferretti, G; Gambaro, G,
)
0.35
" Of the patients who were unable to stop taking theophylline, the Zaditen-and placebo-treated groups recorded average dosage reductions of 62% and 26%, respectively."( A Canadian multicenter study with Zaditen (ketotifen) in the treatment of bronchial asthma in children aged 5 to 17 years.
Brown, CA; Chandra, RK; Ho, P; Hoogerwerf, PE; Kennedy, RJ; Knight, A; Langer, H; Milne, J; Moote, DW; Rackham, A, 1989
)
0.54
" Ten subjects became tachyphylactic to inhaled salbutamol, assessed by a dose-response curve, before and after the 2 weeks of treatment from a metered-dose inhaler."( The effect of ketotifen on bronchial beta-adrenergic tachyphylaxis in normal human volunteers.
Pauwels, R; Van der Straeten, M, 1988
)
0.64
" Ketotifen dosage was 1 mg twice daily in the under 5-year-olds (23 cases) and 2 mg twice daily in the remainder."( Ketotifen in the young asthmatic--a double-blind placebo-controlled trial.
Garg, RA; MacDonald, TH; White, MP,
)
2.48
"267 asthmatic children received ketotifen orally at a dosage of 1 mg twice daily for three months."( Evaluation of ketotifen in the prophylactic treatment of bronchial asthma in children.
Freire, CA; Naspitz, CK,
)
0.78
"This study was designed to assess the acute effect of 1 mg of orally administered ketotifen on the dose-response curve to both histamine and methacholine, in 15 patients with bronchial asthma."( Acute effect of ketotifen on the dose-response curve of histamine and methacholine in asthma.
Barja, S; Cruz, E; Ferretti, R; Lisboa, C; Moran, J; Moreno, R; Sanchez, I, 1985
)
0.84
" Only the ketotifen and clemastine groups differed significantly from the placebo group on shifting log dose-response curves of inhaled histamine."( Long-term modification on histamine-induced bronchoconstriction by disodium cromoglycate and ketotifen versus placebo.
Colas Sanz, C; de Barrio Fernandez, M; Gozalo Reques, F; Herrero Lopez, T; Rubio Sotes, M; Senent Sanchez, C, 1985
)
0.89
" Ketotifen in the higher dosage caused a slight reduction in salbutamol usage and a modest improvement in breathing in patients not already receiving inhaled corticosteroids."( Ketotifen in adult asthma.
Dyson, AJ; Mackay, AD, 1980
)
2.61
" Ketotifen markedly differs in this respect, inhibiting according to a bell-shaped dose-response curve and at concentrations closely comparable to that of DSCG."( Inhibition of allergen-mediated histamine release from human cells by ketotifen and oxatomide. Comparison with other H1 antihistamines.
Radermecker, M, 1981
)
1.41
" Monthly control of the additional medication received, specifying type of medication, dosage and length of time administered (bronchodilators, antihistamines, antibiotics, etc."( [Ketotifen in childhood asthma].
Botey, J; Eseverri, JL; Ibero, M; Malet, A; Marin, A,
)
1.04
" 3 times a day, and a total dosage ranging from 28 to 180 mg."( [Ketotifen in the treatment of chronic urticaria and angioneurotic edema].
Carapeto, FJ; Piñol, J,
)
1.04
" These include responder rate in both extrinsic and intrinsic asthma, pharmacokinetics and dosage in children, reduction in the consumption of corticosteroids and bronchodilators, and avoidance of side effects."( Ketotifen in the prophylaxis of bronchial asthma.
Craps, L, 1982
)
1.71
" Percentage of dosage of beta 2 adrenergics inhaled as against the total of beta 2 (oral and inhaled)."( [Evaluation of the impact of a care program for asthmatic children on the quality of anti-asthma drug prescriptions].
Alba, F; Gimeno, J; González, M; Madridejos, R, 1995
)
0.29
" Ketoifen (100 mumol/L) did not affect the cumulative dose-response relationship to exogenous substance P (0."( Ketotifen modulates noncholinergic contraction in guinea pig airways in vitro by a prejunctional nonhistamine receptor.
Demedts, MM; Pype, JL; Verleden, GM, 1994
)
1.73
"Combined treatment with propranolol and reserpine enhanced acetylcholine-induced dose-response curves for bronchoconstriction in guinea pigs in vivo."( Pharmacological model for airway hypersensitivity produced by propranolol and reserpine in guinea pigs.
Goto, S; Inagaki, N; Koda, A; Nagai, H, 1993
)
0.29
" OVA or Japanese cedar pollen induced the allergic conjunctivitis, depending on the challenge dosage (OVA)."( [Effect of fenitrothion on experimental allergic conjunctivitis].
Kato, H; Kishida, F; Kogiso, S; Nakamura, Y; Nakatsuka, I, 1996
)
0.29
" During the baseline period, the mean daily ICS dosage was 432 micrograms in the ketotifen group versus 408 micrograms in the placebo group (NS)."( Does ketotifen have a steroid-sparing effect in childhood asthma?
Canny, GJ; Levison, H; Reisman, J, 1997
)
1.04
" Children with newly or previously diagnosed ulcerative colitis with mild-moderate disease activity were treated with ketotifen at a dosage of 4 mg daily for eight weeks."( Ketotifen therapy for acute ulcerative colitis in children: a pilot study.
Griffiths, AM; Jones, NL; Roifman, CM; Sherman, P, 1998
)
1.95
" These effects were well maintained after chronic dosing with no signs of beta1-adrenoceptor desensitization."( Ketotifen and cardiovascular effects of xamoterol following single and chronic dosing in healthy volunteers.
Brodde, OE; Daul, AE; Karl, I; Mennicke, K; Philipp, T; Schäfers, RF, 1999
)
1.75
" Compliance with therapy in adolescents in particularly low if the dosing regimen is more than twice daily, with poor inhaler technique contributing to ineffective control."( The problems of treating adolescent asthma: what are the alternatives to inhaled therapy?
Kemp, J; Price, J, 1999
)
0.3
"025% ophthalmic solution, when dosed ocularly, offered protecdon against the nasal signs and symptoms of acute allergic rhinoconjunctival reaction as induced by the CAC model."( A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.
Crampton, HJ, 2002
)
0.55
" Responders were re-randomized to a 4-week twice daily dosing regimen with a CPT 8 hours after the final dose."( Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
Abelson, MB; Casey, R; Dubiner, H; Greiner, JV; Kapik, BM; Lonsdale, J; Mundorf, T; Parver, L; Shams, NB, 2003
)
0.63
" Comparative study of the pruritogenic activity revealed that histamine possessed a potent effect characterized by a dose-response relationship; however, prostaglandin D2 failed to induce this response."( Itch-scratch responses induced by lysophosphatidic acid in mice.
Hashimoto, T; Momose, K; Ohata, H, 2004
)
0.32
"5 days delivering a therapeutically relevant dosage and was fit to a power law model indicating zero-order release characteristics with n=0."( Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow.
Ali, M; Byrne, ME; Hong, JW; Horikawa, S; Saha, J; Venkatesh, S, 2007
)
0.34
" Alternative dosage forms such as liquids or oral disintegrating tablets are available for most agents, allowing ease of administration to most young children and infants; however, limited data are available regarding use in infants for most agents, except desloratadine, cetirizine and montelukast."( Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast.
Moeller, ML; Nahata, MC; Phan, H, 2009
)
0.35
" The majority of lenses were able to match or exceed the total amount of KF commonly administered to the eye using twice-daily dosing of commercially available (0."( Delivery of ketotifen fumarate by commercial contact lens materials.
Hui, A; Jones, L; Soluri, A, 2012
)
0.76
" Based on these results, although all the above products are identical in dosage form and active ingredient, the differences in pharmaceutical properties, such as container operations and drug-solution spraying/attachment, may markedly influence patients' subjective opinions."( Generic selection criteria for safety and patient benefit [V]: Comparing the pharmaceutical properties and patient usability of original and generic nasal spray containing ketotifen fumarate.
Ami, S; Goto, M; Ishii, F; Nozawa, M; Shimokawa, K; Wada, Y,
)
0.33
" Using these complexes, the quantitative determination of KT in its dosage form was successful."( Charge Transfer Complexes of Ketotifen with 2,3-Dichloro-5,6-dicyano-
AlMasoud, N; AlRabiah, H; Bakheit, A; Mostafa, GAE, 2021
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-asthmatic drugA drug used to treat asthma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
organosulfur heterocyclic compound
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
cyclic ketone
piperidines
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Ketotifen H1-Antihistamine Action87

Protein Targets (79)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency43.64860.002541.796015,848.9004AID1347395
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.11880.006038.004119,952.5996AID1159521
GLS proteinHomo sapiens (human)Potency19.95260.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency30.05340.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency3.98050.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency14.26630.000221.22318,912.5098AID1259243; AID1259247; AID743036
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency26.67950.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency17.79230.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
cytochrome P450 2D6Homo sapiens (human)Potency1.38030.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency4.77160.001019.414170.9645AID743094
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency26.67950.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency23.71010.001723.839378.1014AID743083
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency5.37250.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency6.54530.00255.840031.6228AID899
D(1A) dopamine receptorHomo sapiens (human)Potency1.22820.02245.944922.3872AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency0.00270.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.01190.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency24.41260.000323.4451159.6830AID743065; AID743067
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency13.09180.00669.809418.4927AID1347050
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.81780.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.58490.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.58890.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.39810.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency1.58220.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.79430.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency6.11931.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency11.22020.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.58491.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.75690.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
hepatocyte nuclear factor 4-alpha isoform 2Homo sapiens (human)IC50 (µMol)39.84101.41705.08667.8660AID651760
perilipin-5Homo sapiens (human)IC50 (µMol)39.84100.98503.45659.4680AID651759; AID651761
perilipin-1Homo sapiens (human)IC50 (µMol)39.84100.92503.30339.6190AID651766
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform aHomo sapiens (human)IC50 (µMol)39.84100.92503.58289.6190AID651759; AID651761; AID651766
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.16000.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.08400.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)583.50000.11007.190310.0000AID1209455; AID1449628
Glutathione reductase, mitochondrialHomo sapiens (human)Ki0.80000.80003.45006.1000AID1803039
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.83800.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.29800.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)1.00900.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.14100.00000.79519.1201AID625154
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.37400.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.26900.00000.72926.9183AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)2.18700.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.82000.00010.807410.0000AID625201
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)100.00000.00011.68479.3200AID6953
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)1.11200.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.26800.00000.59729.1201AID625151
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)Ki5.20001.19105.12919.9410AID1802951
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.71000.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.32400.00020.725710.0000AID625202
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)2.53700.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki1.45000.00010.739610.0000AID625190
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)2.20900.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.46800.00000.54057.7600AID625153
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.87200.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki0.43600.00010.836310.0000AID625252
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)4.12900.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki4.06000.00062.197310.0000AID625270
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)3.72700.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki1.83200.00000.360910.0000AID625200
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.03100.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.01240.00000.385510.0000AID537325; AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.16000.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.14180.00010.954910.0000AID537327; AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)2.53700.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.45000.00031.29679.2440AID625190
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.00110.00000.44365.1768AID595800; AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.00010.00000.511010.0000AID537324; AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)1.96300.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.66700.00000.602010.0000AID625254
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.04600.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.03030.00030.769310.0000AID537326; AID625217
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)1.14100.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.53000.00020.522910.0000AID625221
6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)Ki8.30000.01002.74508.3000AID1802944
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km71.66677.00007.00007.0000AID214939; AID624633
UDP-glucuronosyltransferase 1A3Homo sapiens (human)Km174.00007.34007.34007.3400AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (321)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cellular oxidant detoxificationGlutathione reductase, mitochondrialHomo sapiens (human)
cellular response to oxidative stressGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione metabolic processGlutathione reductase, mitochondrialHomo sapiens (human)
cell redox homeostasisGlutathione reductase, mitochondrialHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
pentose-phosphate shuntGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
lipid metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADPH regenerationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glutathione metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose-phosphate shunt, oxidative branchGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to iron(III) ionGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein glutathionylationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to organic cyclic compoundGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
substantia nigra developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to foodGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cellular response to oxidative stressGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
erythrocyte maturationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
regulation of neuron apoptotic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to ethanolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
ribose phosphate biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose 6-phosphate metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
xenobiotic metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
estrogen metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
bile acid secretionUDP-glucuronosyltransferase 1A3Homo sapiens (human)
retinoic acid metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
flavonoid glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
xenobiotic glucuronidationUDP-glucuronosyltransferase 1A3Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A3Homo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
pentose-phosphate shunt6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose-phosphate shunt, oxidative branch6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
pentose biosynthetic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
D-gluconate catabolic process6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (65)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
electron transfer activityGlutathione reductase, mitochondrialHomo sapiens (human)
NADP bindingGlutathione reductase, mitochondrialHomo sapiens (human)
glutathione-disulfide reductase (NADPH) activityGlutathione reductase, mitochondrialHomo sapiens (human)
flavin adenine dinucleotide bindingGlutathione reductase, mitochondrialHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
glucose-6-phosphate dehydrogenase activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
identical protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein homodimerization activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A3Homo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
phosphogluconate dehydrogenase (decarboxylating) activity6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
NADP binding6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
mitochondrial matrixGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
external side of plasma membraneGlutathione reductase, mitochondrialHomo sapiens (human)
extracellular exosomeGlutathione reductase, mitochondrialHomo sapiens (human)
cytosolGlutathione reductase, mitochondrialHomo sapiens (human)
mitochondrionGlutathione reductase, mitochondrialHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
cytoplasmGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytoplasmic side of plasma membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
centriolar satelliteGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
extracellular exosomeGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A3Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A3Homo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
nucleus6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
extracellular exosome6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
cytosol6-phosphogluconate dehydrogenase, decarboxylatingHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (192)

Assay IDTitleYearJournalArticle
AID1346037Human H1 receptor (Histamine receptors)2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID222309Inhibition of Histamine mediator release form passively sensitized human lung upon antigen challenge at 1 ug/mL dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID78852Ability to inhibit histamine-induced contractions of isolated guinea pig ileum1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID178102Antiallergic activity by passive cutaneous anaphylaxis assay upon peroral administration of 20 mg/kg in rat1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acryl amides.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179233Compound was tested for the inhibition of release of histamine in rat passive peritoneal anaphylaxis1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
AID537324Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
AID182545Compound was tested for percent inhibition, at 3.3 mg/kg administered intraperitoneally against histamine by Dunnett's test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID173540Percentage decrease in antiallergic activity against cutaneous reaction to histamine in rat, by oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID222314Inhibition of Slow reacting substance of anaphylaxis (SRS-A) mediator release form passively sensitized human lung upon antigen challenge at 1 ug/mL dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID661673Inhibition of DNP-BSA-induced degranulation in rat RBL2H3 cells assessed as reduction in beta-hexosaminidase release after 20 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11
Synthesis of norlignans and in vitro inhibitory activity of antigen-induced degranulation.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID624633Drug glucuronidation reaction catalyzed by human recombinant UGT1A42005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID182547Compound was tested for percent inhibition, at 3.3 mg/kg administered intraperitoneally against serotonin by Dunnett's test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID78049Compound was tested for the inhibition of guinea pig active lung anaphylaxis (ALA) at 0.001 mg/kg iv1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID77133Antibronchospatic activity determined by histamine stimulated bronchospasm inhibition in guinea pigs after(i.v.) administration1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID80564Time of dosing of compound before antigen challenge in conscious sensitized guinea pig at 2 mg/kg po dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID624632Drug glucuronidation reaction catalyzed by human recombinant UGT1A32005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID222308Inhibition of Histamine mediator release form passively sensitized human lung upon antigen challenge at 10 ug/mL dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID181506Ability to inhibit the release of histamine in the rat peritoneal fluids by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
N-benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1124123Antianaphylactic activity in ovalbumin/ovalbumin aerosol sensitized guinea pig bronchospasm model assessed as ratio of mean collapse time after pretreatment with compound in presence of mepyramine to mean collapse time of control animal at 1 x 2 mg/kg, po1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Antianaphylactic agents. 1. 2-(Acylamino)oxazoles.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID182537Compound was tested for percent inhibition, at 0.37 mg/kg administered intraperitoneally against serotonin by Dunnett's test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID182546Compound was tested for percent inhibition, at 3.3 mg/kg administered intraperitoneally against rat passive cutaneous anaphylaxis by Dunnett's test1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID6953Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acryl amides.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID76413Inhibition of guinea pig ALA at a dose of 1 mg/kg 7 hr after postdosing orally; ND= No data1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID74315Mean collapse time after pretreatment with compound divided by mean collapse time of untreated control animals at 2 mg/kg po dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID165615Test against PAF-induced aggregation of rabbit platelets in vitro1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID177340Inhibition of cutaneous histamine reaction in rats.1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID595887In vivo antihistaminic activity at histamine H1 receptor in ddY mouse assessed as inhibition of histamine-induced skin vascular permeability po administered 1 hr before histamine challenge by Evan's blue staining2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID86245The compound was tested in vitro for binding affinity against histamine H1 receptor from guinea pig cerebellum, using [3H]pyrilamine as radioligand at 0.1 uM1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID76411Inhibition of guinea pig ALA at a dose of 1 mg/kg 24 hr after postdosing orally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID595804Antiinflammatory activity in ovalbumin-sensitized BALB/c mouse biphasic allergic model assessed as immediate type reaction at 10 mg/kg, po administered 1 hr before ovalbumin challenge measured 1 hr after elicitation by ear swelling assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID595800Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID75528Percent decrease in bronchodilator activity against histamine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID113865Inhibitory effect on histamine-induced increase in vascular permeability in mice upon oral administration1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Amphoteric drugs. 3. Synthesis and antiallergic activity of 3-[(5,11-dihydro[1]benzoxepino[4,3-b]pyridin-11- ylidene)piperidino]propionic acid derivatives and related compounds.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID74052Ability to inhibit histamine phase of antigen-induced bronchoconstriction in vivo in pulmonary function assays in which Guinea pigs were dosed orally 5 hours prior to test1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID1124117Antianaphylactic activity in human chopped lung treated with atopic serum isolated from patients allergic to cocksfoot pollen assessed as inhibition of antigen-induced histamine release at 10 ug/mL after 15 mins relative to control1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Antianaphylactic agents. 1. 2-(Acylamino)oxazoles.
AID537325Antagonist activity at human 5HT2A receptor expressed in HEK cells assessed as inhibition of intracellular calcium accumulation by aequorin assay2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
AID90054H1-antihistamine activity on guinea pig ileum1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
N-benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID141584Binding affinity for Muscarinic acetylcholine receptor M1 from rat striatum, using [3H]quinuclidinyl benzilate as radioligand at 10 uM.1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID179231Compound was tested for the inhibition of release of extravasation in rat passive peritoneal anaphylaxis1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
AID79725H1-antihistamine activity in guinea pig ileum1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Studies on 1,2,3-triazoles. 13. (Piperazinylalkoxy) [1]benzopyrano[2,3-d]-1,2,3-triazol-9(1H)-ones with combined H1-antihistamine and mast cell stabilizing properties.
AID179252Compound was tested in vivo for the inhibition of serotonin release in rat peritoneal cell1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID76410Inhibition of guinea pig ALA at a dose of 1 mg/kg 24 hr after postdosing intraperitoneally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1124121Antianaphylactic activity in ovalbumin/ovalbumin aerosol sensitized guinea pig bronchospasm model assessed as ratio of mean collapse time after pretreatment with compound to mean collapse time of control animal at 1 x 2 mg/kg, po compound administered pri1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Antianaphylactic agents. 1. 2-(Acylamino)oxazoles.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID76560Inhibition of slow reacting substance of anaphylaxis (SRS-A) release from sensitized guinea pig chopped lung upon antigen challenge at 10 ug/mL1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID78010Anti-histaminic activity was measured in guinea pig trachea1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acryl amides.
AID537326Antagonist activity at human 5HT2B receptor expressed in human SH-SY5Y cells by FLIPR assay2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID595805Antiinflammatory activity in ovalbumin-sensitized BALB/c mouse biphasic allergic model assessed as late type reaction at 10 mg/kg, po administered 1 hr before ovalbumin challenge measured 24 hrs after elicitation by ear swelling assay2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.
AID113417Antiallergic activity was evaluated by inhibitory effect on compound 48/80-induced lethality in rats at a dose 0.01 (mg/kg, po)1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Amphoteric drugs. 3. Synthesis and antiallergic activity of 3-[(5,11-dihydro[1]benzoxepino[4,3-b]pyridin-11- ylidene)piperidino]propionic acid derivatives and related compounds.
AID77121The compound was tested in vivo for the inhibition of IgG1-mediated bronchoconstriction in guinea pig at 0.03 mg/kg administered perorally1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID1124118Antianaphylactic activity in human chopped lung treated with atopic serum isolated from patients allergic to cocksfoot pollen assessed as inhibition of antigen-induced slow-reacting substance of anaphylaxis release at 10 ug/mL after 15 mins relative to co1979Journal of medicinal chemistry, Apr, Volume: 22, Issue:4
Antianaphylactic agents. 1. 2-(Acylamino)oxazoles.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID76408Inhibition of guinea pig ALA at a dose of 1 mg/kg 1 hr after postdosing intraperitoneally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID76412Inhibition of guinea pig ALA at a dose of 1 mg/kg 7 hr after postdosing intraperitoneally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID181505Ability to inhibit the release of extravasated dye in the rat peritoneal fluids by 50%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
N-benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID213197In vivo toxic effect was determined in mouse after oral administration with 10% aqueous acacia gum; value ranges from 0.50-0.681987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID74310Mean collapse time after pretreatment with compound and mepyramine divided by mean collapse time of mepyramine-dosed control animals at 2 mg/kg po dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID33525Inhibition of mast cell degranulation was assessed in female albino rats at a dose of 2 umol/kg iv1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID89975Inhibitory activity against histamine release in human basophil1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure-activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acryl amides.
AID234738Selectivity as the ratio of ID50 value to that of ED50 value in mice.1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Amphoteric drugs. 3. Synthesis and antiallergic activity of 3-[(5,11-dihydro[1]benzoxepino[4,3-b]pyridin-11- ylidene)piperidino]propionic acid derivatives and related compounds.
AID173539Percent decrease in antiallergic activity by antigen/antibody reaction assay in rat by oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID76414Inhibition of guinea pig ALA at a dose of 1 mg/kg 8 hr after postdosing intraperitoneally; ND= No data1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID213020In vivo toxic effect was determined in mouse after intraperitoneal administration with 10% aqueous acacia gum; value ranges from 0.29-0.421987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID537327Antagonist activity at human 5HT2C receptor expressed in human SH-SY5Y cells by FLIPR assay2010Journal of medicinal chemistry, Nov-11, Volume: 53, Issue:21
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.
AID78180Histamine induced in lethality in guinea pigs at 8 hr after oral dose of 0.02 mg/kg1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Amphoteric drugs. 3. Synthesis and antiallergic activity of 3-[(5,11-dihydro[1]benzoxepino[4,3-b]pyridin-11- ylidene)piperidino]propionic acid derivatives and related compounds.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID76415Inhibition of guinea pig ALA at a dose of 1 mg/kg 8 hr after postdosing orally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID182701Compound was tested for the inhibition of rat passive cutaneous anaphylaxis (PCA) at 0.37 mg/kg dose ip (1h pretreatment)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID183425Rat PCA Test(50% inhibition of spot areas)in the female albino rats after oral administration in 10% aqueous acacia gum; value ranges from 1.7-2.41987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID87373Ex vivo inhibition of [3H]mepyramine binding to mouse brain membrane H1 receptor after oral administration1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Amphoteric drugs. 3. Synthesis and antiallergic activity of 3-[(5,11-dihydro[1]benzoxepino[4,3-b]pyridin-11- ylidene)piperidino]propionic acid derivatives and related compounds.
AID74177Ability to inhibit histamine phase of platelet activating factor (PAF)-induced bronchoconstriction in vivo in pulmonary function assays in which Guinea pigs were dosed orally 5 hours prior to test; not tested1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID180554The compound was tested in vivo for inhibitory effect on 48-h homologous passive cutaneous anaphylaxis (PCA) in rats administered perorally1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Synthesis and antiallergic activity of 11-(aminoalkylidene)-6,11-dihydrodibenz[b,e]oxepin derivatives.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76784Compound was tested for the inhibition of guinea pig active lung anaphylaxis (ALA) administered intravenously1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID222312Inhibition of Slow reacting substance of anaphylaxis (SRS-A) mediator release form passively sensitized human lung upon antigen challenge at 10 ug/mL dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID76409Inhibition of guinea pig ALA at a dose of 1 mg/kg 1 hr after postdosing orally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID78052Inhibition of histamine release from sensitized guinea pig chopped lung upon antigen challenge at 10 ug/mL.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Antianaphylactic benzophenones and related compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID182535Compound was tested for percent inhibition, at 0.37 mg/kg administered intraperitoneally against histamine1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID178093Antiallergic activity in the rat PCA assay following oral administration 1 hour before antigen challenge. Five animals were used in this experiment.1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application i
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID176485Compound concentration inhibiting 48 hr homologous passive cutaneous Anaphylaxis in rats peroral administration1993Journal of medicinal chemistry, Feb-05, Volume: 36, Issue:3
Dibenz[b,e]oxepin derivatives: novel antiallergic agents possessing thromboxane A2 and histamine H1 dual antagonizing activity. 1.
AID183152Rat PCA Test(50% inhibition of spot areas)in the female albino rats after (ip) administration in 10% aqueous acacia gum; ND means no data1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
1-(2-pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic, and mast cell stabilizing activities.
AID178873Compound was tested for the inhibition of rat passive cutaneous anaphylaxis (PCA) administered intraperitoneally1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Indolo[2,1-c][1,4]benzodiazepines: a new class of antiallergic agents.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1802944In Vitro Assay from Article 10.3109/14756360903257900: \\Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.\\2010Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 25, Issue:4
Effects of some drugs on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro study.
AID1803039Activity Assay from Article 10.3109/14756366.2011.572879: \\In vitro effects of some drugs on human erythrocyte glutathione reductase.\\2012Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 27, Issue:1
In vitro effects of some drugs on human erythrocyte glutathione reductase.
AID1802951In Vitro Inhibition Assay from Article 10.3109/14756360903489581: \\Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.\\2010Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,086)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990426 (39.23)18.7374
1990's291 (26.80)18.2507
2000's193 (17.77)29.6817
2010's132 (12.15)24.3611
2020's44 (4.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 89.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index89.18 (24.57)
Research Supply Index7.31 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index171.68 (26.88)
Search Engine Supply Index2.10 (0.95)

This Compound (89.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials275 (22.69%)5.53%
Reviews78 (6.44%)6.00%
Case Studies83 (6.85%)4.05%
Observational0 (0.00%)0.25%
Other776 (64.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (35)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Montelukast, on Pediatric Bronchial Asthma in Multicenter Comparative Double-Blind Clinical Study (Phase IV) With Ketotifen Fumarate [NCT00446056]Phase 4188 participants (Actual)Interventional2003-09-25Completed
A Double-Blind, Placebo-Controlled, 2-Part, Single Ascending Dose and Multiple Dose Cohort Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Norketotifen in Healthy Subjects [NCT03712163]Phase 174 participants (Actual)Interventional2018-10-15Completed
Phase III Double-blind Comparative Study of WAL801CL Dry Syrup in Paediatric Perennial Allergic Rhinitis [NCT02182544]Phase 3151 participants (Actual)Interventional2001-06-30Completed
A Randomized, Double-Masked, Crossover Study to Evaluate the Safety and Comfort of AL-4943A Ophthalmic Solution, 0.7% [NCT01326858]Phase 150 participants (Actual)Interventional2011-04-30Completed
Clinical Evaluation of Etafilcon A With Ketotifen [NCT03388138]Phase 2143 participants (Actual)Interventional2017-12-06Completed
Phase III Double-Blind Comparative Study of WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients [NCT02182557]Phase 3162 participants (Actual)Interventional2001-06-30Completed
Ketotifen in Non-Alcoholic Fatty Liver Disease Patients [NCT05616442]Phase 460 participants (Anticipated)Interventional2022-12-01Not yet recruiting
A Prospective, Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen [NCT00836485]Phase 2122 participants (Actual)Interventional2009-02-28Completed
Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19 [NCT04435028]111 participants (Actual)Observational2019-01-14Completed
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers [NCT00569777]Phase 3310 participants (Actual)Interventional2007-10-31Completed
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) [NCT02673840]Phase 4110 participants (Anticipated)Interventional2015-03-31Recruiting
A Double-blind, Parallel, Active Comparator Controlled, Randomized Trial; Comparison of the Efficacy and Safety in Children With Perennial Allergic Rhinitis of Cetirizine Tablets Versus Ketotifen Dry Syrup [NCT00639587]Phase 3149 participants (Actual)Interventional2002-08-31Completed
PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2 [NCT03582176]Phase 3381 participants (Anticipated)Interventional2019-04-26Recruiting
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer [NCT05624138]Phase 364 participants (Anticipated)Interventional2022-11-09Recruiting
A Single-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers [NCT00889252]Phase 3250 participants (Actual)Interventional2009-04-30Completed
Randomized, Double Blind, Placebo Controlled Trial of Ketotifen in Patients With Elbow Fractures or Dislocations [NCT01902017]Phase 2152 participants (Actual)Interventional2013-06-30Completed
Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Proof-of-Concept Clinical Trial to Evaluate the Efficacy of Ketotifen and Indomethacin for Mild and Moderate COVID-19 in A [NCT05007522]Phase 3150 participants (Anticipated)Interventional2022-05-03Recruiting
Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia [NCT02484248]Phase 340 participants (Anticipated)Interventional2015-08-31Active, not recruiting
Evaluation of Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model [NCT05579730]Phase 3187 participants (Actual)Interventional2022-11-18Completed
Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase. [NCT00426023]Phase 348 participants (Anticipated)Interventional2007-02-28Completed
Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis [NCT05591755]Phase 3228 participants (Actual)Interventional2022-10-22Completed
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens We [NCT00445874]Phase 3120 participants (Anticipated)Interventional2007-02-28Completed
A Multi-center, Double-masked, Randomized, Placebo-controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis. [NCT00770133]Phase 3141 participants (Actual)Interventional2010-02-28Completed
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens as Compared to Placebo in the Prevention of Allergic Conjunctivitis in a Population of Allergic Contact Lens We [NCT00432757]Phase 3120 participants (Anticipated)Interventional2007-01-31Completed
Proof of Concept Trial to Test the Efficacy of Treatment With Ketotifen on Pain Sensitivity and Association Between Level of Activity and Reactivity of White Blood Cells and Pain Sensitivity in Teenagers With Chronic Widespread Pain [NCT02984397]Phase 344 participants (Actual)Interventional2016-12-31Completed
A Multi-Center, Double-Masked, Randomized, Vehicle- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Bilastine Ophthalmic Solution 0.6% Compared to Vehicle and Zaditen (Ketotifen Ophthalmic Solution 0.025%) for the Treatment of A [NCT03479307]Phase 3228 participants (Actual)Interventional2018-04-07Completed
Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis [NCT00133627]Phase 4229 participants (Actual)Interventional2005-04-30Completed
Influence of Antipruritics on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin [NCT04399148]13 participants (Actual)Interventional2019-06-11Completed
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult [NCT05815758]511 participants (Actual)Observational2023-04-20Completed
A Prospective, Randomized, Case Controlled, Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization in Children With Peanut Allergies. [NCT01625715]Phase 26 participants (Anticipated)Interventional2011-01-31Active, not recruiting
Study Withdrawn Prior to Determining Official Title [NCT00375596]Phase 20 participants (Actual)InterventionalWithdrawn(stopped due to Study withdrawn without starting or enrolling subjects due to a business decision to not proceed with the project.)
A Multi-Center, Double-Masked, Randomized, Vehicle and Active Controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis [NCT00769886]Phase 3144 participants (Actual)Interventional2008-10-31Completed
A Randomized Controlled Study on the Efficacy and Safety of Ketotifen in Primary PCI Patients With STEMI [NCT05511831]Phase 460 participants (Anticipated)Interventional2022-09-01Not yet recruiting
Novel Use of Ketotifen (Mast Cell Stabilizer) in Fibromyalgia: A Pilot Study [NCT01553318]Phase 351 participants (Actual)Interventional2012-03-31Completed
A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study) [NCT01840605]Phase 3303 participants (Actual)Interventional2013-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00569777 (19) [back to overview]Corneal Endothelial, Change From Baseline
NCT00569777 (19) [back to overview]Cells in Anterior Chamber, Change From Baseline
NCT00569777 (19) [back to overview]Conjunctival Chemosis, Change From Baseline
NCT00569777 (19) [back to overview]Conjunctival Redness, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Edema, Change From Baseline
NCT00569777 (19) [back to overview]Dilated Ophthalmoscopy - Vitreous, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Erosion, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Staining - Central, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Staining - Inferior, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Staining - Nasal, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Staining - Superior, Change From Baseline
NCT00569777 (19) [back to overview]Corneal Staining - Temporal, Change From Baseline
NCT00569777 (19) [back to overview]Dilated Ophthalmoscopy - Fundus, Change From Baseline
NCT00569777 (19) [back to overview]Flare in Anterior Chamber, Change From Baseline
NCT00569777 (19) [back to overview]Intraocular Pressure, Change From Baseline
NCT00569777 (19) [back to overview]Lens Pathology, Change From Baseline
NCT00569777 (19) [back to overview]Lid and Lid Margin Erythema, Change From Baseline
NCT00569777 (19) [back to overview]Lid and Lid Margin Swelling, Change From Baseline
NCT00569777 (19) [back to overview]Visual Acuity Assessment
NCT00769886 (8) [back to overview]Eyelid Swelling
NCT00769886 (8) [back to overview]Episcleral Redness
NCT00769886 (8) [back to overview]Conjunctival Hyperemia
NCT00769886 (8) [back to overview]Ciliary Redness
NCT00769886 (8) [back to overview]Chemosis
NCT00769886 (8) [back to overview]Percentage of Eyes With Ocular Mucus Drainage
NCT00769886 (8) [back to overview]Percentage of Eyes With Tearing
NCT00769886 (8) [back to overview]Ocular Itching
NCT00770133 (8) [back to overview]Ciliary Redness
NCT00770133 (8) [back to overview]Conjunctival Redness
NCT00770133 (8) [back to overview]Episcleral Redness
NCT00770133 (8) [back to overview]Eyelid Swelling
NCT00770133 (8) [back to overview]Ocular Itching
NCT00770133 (8) [back to overview]Percentage of Eyes With hTearing
NCT00770133 (8) [back to overview]Percentage of Eyes With Ocular Mucus Discharge
NCT00770133 (8) [back to overview]Chemosis
NCT00889252 (19) [back to overview]Cells in Anterior Chamber, Change From Baseline
NCT00889252 (19) [back to overview]Conjunctival Chemosis, Change From Baseline
NCT00889252 (19) [back to overview]Visual Acuity Assessment
NCT00889252 (19) [back to overview]Dilated Ophthalmoscopy - Fundus, Change From Baseline
NCT00889252 (19) [back to overview]Dilated Ophthalmoscopy - Vitreous, Change From Baseline
NCT00889252 (19) [back to overview]Flare in Anterior Chamber, Change From Baseline
NCT00889252 (19) [back to overview]Intraocular Pressure - Change From Baseline
NCT00889252 (19) [back to overview]Lens Pathology, Change From Baseline
NCT00889252 (19) [back to overview]Lid and Lid Margin Erythema, Change From Baseline
NCT00889252 (19) [back to overview]Lid and Lid Margin Swelling, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Staining - Superior, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Staining - Nasal, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Staining - Inferior, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Staining - Central, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Erosion, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Endothelial, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Edema, Change From Baseline
NCT00889252 (19) [back to overview]Corneal Staining - Temporal, Change From Baseline
NCT00889252 (19) [back to overview]Conjunctival Redness, Change From Baseline
NCT01553318 (3) [back to overview]Change From Baseline in Evoked Pain Score at Week 10
NCT01553318 (3) [back to overview]Change From Baseline in Weekly Average Pain Score on the Visual Analog Scale at Week 10
NCT01553318 (3) [back to overview]Fibromyalgia Impact Questionnaire
NCT01840605 (4) [back to overview]Change From Baseline in Pruritus Score
NCT01840605 (4) [back to overview]Change From Baseline in Pruritus Score
NCT01840605 (4) [back to overview]Percentage of Participants With Patient Impression Score (Reporting Excellent or Very Well Improved in Pruritus)
NCT01840605 (4) [back to overview]Severity of Atopic Dermatitis at 2 Weeks (Change From Baseline)
NCT03388138 (4) [back to overview]The Number of Eyes With Unacceptable Lens Fitting
NCT03388138 (4) [back to overview]Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)
NCT03388138 (4) [back to overview]Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)
NCT03388138 (4) [back to overview]The Number of Eyes With Clinically Significant Slit Lamp Findings
NCT03479307 (1) [back to overview]Ocular Itching

Corneal Endothelial, Change From Baseline

Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Cells in Anterior Chamber, Change From Baseline

Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Conjunctival Chemosis, Change From Baseline

Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Conjunctival Redness, Change From Baseline

Assessment of redness of conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo-0.1

[back to top]

Corneal Edema, Change From Baseline

Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Dilated Ophthalmoscopy - Vitreous, Change From Baseline

Assessment of changes in the vitreous (gel-like fluid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Corneal Erosion, Change From Baseline

Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Corneal Staining - Central, Change From Baseline

Assessment of changes to the surface of the cornea, central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Corneal Staining - Inferior, Change From Baseline

Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Corneal Staining - Nasal, Change From Baseline

Assessment of changes to the surface of cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens-0.1
Placebo0

[back to top]

Corneal Staining - Superior, Change From Baseline

Assessment of changes to the surface of the cornea, upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Corneal Staining - Temporal, Change From Baseline

Assessment of changes to the surface of the cornea, the region towards the outer edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Dilated Ophthalmoscopy - Fundus, Change From Baseline

Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens-0.1
Placebo0

[back to top]

Flare in Anterior Chamber, Change From Baseline

Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Intraocular Pressure, Change From Baseline

(NCT00569777)
Timeframe: baseline and 12 weeks

Interventionmm of mercury (Mean)
K-lens-0.3
Placebo-0.4

[back to top]

Lens Pathology, Change From Baseline

Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo-0.1

[back to top]

Lid and Lid Margin Erythema, Change From Baseline

Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Lid and Lid Margin Swelling, Change From Baseline

Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe. (NCT00569777)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-lens0
Placebo0

[back to top]

Visual Acuity Assessment

Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit. (NCT00569777)
Timeframe: at 12 weeks

InterventionEyes (Number)
K-lens362
Placebo178

[back to top]

Eyelid Swelling

Lid swelling was evaluated by the subject at 7, 15, and 20 minutes post challenge on a 0- 3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0 = None and 3.0 = Severe. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph0.130.250.26
Ketotifen0.320.370.39
Naphazoline0.610.610.59

[back to top]

Episcleral Redness

Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph1.211.411.35
Ketotifen1.521.871.88
Naphazoline1.711.771.68

[back to top]

Conjunctival Hyperemia

Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,,
Interventionunits on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph1.131.391.26
Ketotifen1.491.891.77
Naphazoline1.621.681.53
Vehicle2.242.332.24

[back to top]

Ciliary Redness

Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using a 0-4 scale, allowing 0.5- unit increments, with 0.0 = None and 4.0 = Extremely severe. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionunits on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph1.051.281.15
Ketotifen1.391.791.77
Naphazoline1.661.711.58

[back to top]

Chemosis

Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0 = None and 4.0 = Extremely severe. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph0.220.290.34
Ketotifen0.220.420.41
Naphazoline0.510.660.66

[back to top]

Percentage of Eyes With Ocular Mucus Drainage

Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventioneyes (Count of Units)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph71110
Ketotifen121916
Naphazoline131818

[back to top]

Percentage of Eyes With Tearing

Tearing was evaluated by the subject at 7, 15, and 20 minutes post challenge (absent or present). Tearing was recorded as either absent or present. (NCT00769886)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventioneyes (Count of Units)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
KetoNaph365
Ketotifen1177
Naphazoline231613

[back to top]

Ocular Itching

Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0 = None and 4.0 = Incapacitating itch with an irresistible urge to rub. (NCT00769886)
Timeframe: 3, 5, and 7 minutes post challenge at 14 days

,,,
Interventionscore on a scale (Mean)
3 minutes post-challenge5 minutes post-challenge7 minutes post-challenge
KetoNaph0.500.560.56
Ketotifen0.490.690.72
Naphazoline1.871.901.75
Vehicle1.932.171.97

[back to top]

Ciliary Redness

Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
Ketotifen1.331.761.76
Ketotifen/Naphazoline0.811.051.04
Naphazoline1.491.591.54

[back to top]

Conjunctival Redness

Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,,
Interventionscore on a scale (Mean)
7 minutes post-challeng15 minutes post-challenge20 minutes post-challenge
Ketotifen1.491.801.88
Ketotifen/Naphazoline0.891.131.13
Naphazoline1.631.691.57
Vehicle2.062.262.18

[back to top]

Episcleral Redness

Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
Ketotifen1.511.761.88
Ketotifen/Naphazoline0.911.171.15
Naphazoline1.651.681.60

[back to top]

Eyelid Swelling

Lid swelling was evaluated by the participant at 7, 15, and 20 minutes post challenge on a 0-3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0=None and 3.0=Severe. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
Ketotifen0.20.20.2
Ketotifen/Naphazoline0.20.20.2
Naphazoline0.20.20.2

[back to top]

Ocular Itching

Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0=None and 4.0=Incapacitating itch with an irresistible urge to rub (NCT00770133)
Timeframe: 3, 5, and 7 minutes post challenge at 14 days

,,,
Interventionscore on a scale (Mean)
3 minutes post-challenge5 minutes post-challenge7 minutes post-challenge
Ketotifen0.400.590.56
Ketotifen/Naphazoline0.430.650.60
Naphazoline1.601.671.54
Vehicle1.811.961.84

[back to top]

Percentage of Eyes With hTearing

Tearing was evaluated by the participant at 7, 15, and 20 minutes post challenge. Tearing was recorded as either absent or present. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventioneyes (Count of Units)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
Ketotifen1196
Ketotifen/Naphazoline745
Naphazoline131211

[back to top]

Percentage of Eyes With Ocular Mucus Discharge

Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventioneyes (Count of Units)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
Ketotifen000
Ketotifen/Naphazoline000
Naphazoline000

[back to top]

Chemosis

Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe. (NCT00770133)
Timeframe: 7, 15, and 20 minutes post challenge at 14 days

,,
Interventionscore on a scale (Mean)
7 minutes post-challenge15 minutes post-challenge20 minutes post-challenge
Ketotifen0.280.460.49
Ketotifen/Naphazoline0.270.340.39
Naphazoline0.390.540.54

[back to top]

Cells in Anterior Chamber, Change From Baseline

Assessment of visible cells in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Conjunctival Chemosis, Change From Baseline

Assessment of swelling of the conjunctiva using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Visual Acuity Assessment

Visual acuity was assessed by the investigator using a Snellen visual acuity chart. This outcome counts the number of eyes that had vision of 20/40 or better at the 12 week visit. (NCT00889252)
Timeframe: at the 12 week visit

InterventionEyes (Number)
K-Lens316
Placebo Lens150

[back to top]

Dilated Ophthalmoscopy - Fundus, Change From Baseline

Assessment of changes in abnormalities on the back part of the eye, using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Dilated Ophthalmoscopy - Vitreous, Change From Baseline

Assessment of changes in the vitreous (gel-like fulid of the eye), using the scale: 0=none, 0.5=trace, 1=mild, 2=moderate, 3=severe. (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Flare in Anterior Chamber, Change From Baseline

Assessment of visible protein in the anterior chamber using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Intraocular Pressure - Change From Baseline

(NCT00889252)
Timeframe: baseline and 12 weeks

Interventionmm of mercury (Mean)
K-Lens0.8
Placebo Lens0.6

[back to top]

Lens Pathology, Change From Baseline

Assessment of the clarity of the intraocular lens using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Lid and Lid Margin Erythema, Change From Baseline

Assessment of lid redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Lid and Lid Margin Swelling, Change From Baseline

Assessment of lid swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Staining - Superior, Change From Baseline

Assessment of changes to the surface of the cornea, the upper region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Staining - Nasal, Change From Baseline

Assessment of changes to the surface of the cornea, the region towards the nose, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Staining - Inferior, Change From Baseline

Assessment of changes to the surface of the cornea, the bottom region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens-0.1
Placebo Lens0.0

[back to top]

Corneal Staining - Central, Change From Baseline

Assessment of changes to the surface of the cornea, the central region, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Erosion, Change From Baseline

Assessment of corneal erosion using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Endothelial, Change From Baseline

Assessment of the posterior cornea using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Edema, Change From Baseline

Assessment of corneal swelling using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Corneal Staining - Temporal, Change From Baseline

Assessment of changes to the surface of the cornea, the region towards the edge of the face, as evaluated by the degree of staining with sodium fluorescein solution, using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens0
Placebo Lens0

[back to top]

Conjunctival Redness, Change From Baseline

Assessment of conjunctival redness using the following scale: 0=none, 1=mild, 2=moderate, 3=severe, 4=very severe (NCT00889252)
Timeframe: baseline and 12 weeks

InterventionUnits on a scale (Mean)
K-Lens-0.3
Placebo Lens-0.1

[back to top]

Change From Baseline in Evoked Pain Score at Week 10

Change in evoked pain score from baseline to week 10 (scale range -20 to +20): interpretation= the more negative the value is, the larger the reduction in sensitivity to pressure pain stimuli (NCT01553318)
Timeframe: baseline and week 10

Interventionunits on a scale (Mean)
Ketotifen-0.33
Placebo-0.27

[back to top]

Change From Baseline in Weekly Average Pain Score on the Visual Analog Scale at Week 10

Change in weekly average pain score from baseline to week 10 (range from -10 to +10): interpretation= the more negative the value is, the larger reduction in pain severity at week 10 is (NCT01553318)
Timeframe: baseline and week 10

Interventionunits on a scale (Mean)
Ketotifen-1.33
Placebo-1.54

[back to top]

Fibromyalgia Impact Questionnaire

Change in global symptom severity [scale range from -100 to +100] = the more negative the value is, the greater the improvement in overall symptom severity (NCT01553318)
Timeframe: baseline and week 10

Interventionunits on a scale (Mean)
Ketotifen-12.13
Placebo-12.27

[back to top]

Change From Baseline in Pruritus Score

The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe). (NCT01840605)
Timeframe: Baseline and 1 weeks

Interventionunits on a scale (Least Squares Mean)
TAU-284-0.425
Ketotifen Fumarate-0.510

[back to top]

Change From Baseline in Pruritus Score

The pruritus symptoms score were rated on 5-point scale ranging from 0 (none) to 4 (severe). (NCT01840605)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Least Squares Mean)
TAU-284-0.669
Ketotifen Fumarate-0.638

[back to top]

Percentage of Participants With Patient Impression Score (Reporting Excellent or Very Well Improved in Pruritus)

Patient impression score were rated on 5-point scale ranging from 0 to 4 (4 excellent, 3 very well, 2 well, 1fair, 0 poor). (NCT01840605)
Timeframe: Week 2

Interventionpercentage of participants (Number)
TAU-28465.6
Ketotifen Fumarate65.1

[back to top]

Severity of Atopic Dermatitis at 2 Weeks (Change From Baseline)

Severity score were rated on 5-point scale ranging from 0 (none) to 4 (severe). (NCT01840605)
Timeframe: Baseline and 2 weeks

Interventionunits on a scale (Least Squares Mean)
TAU-284-0.8
Ketotifen Fumarate-0.7

[back to top]

The Number of Eyes With Unacceptable Lens Fitting

Lens fit was assessed for each subject and eye using a biomicroscope. Unacceptable lens fit was assessed at all scheduled and unscheduled visits. A subject was deemed to have an unacceptable lens fitting if they met any of the following criteria: (1) Limbal exposure at primary gaze with extreme eye movement, (2) edge lift, (3) excessive movement in primary up gaze, (4) insufficient movement in all three of the following conditions: primary gaze, up gaze and push up test. The number of eyes with unacceptable lens fitting was reported for each lens type. (NCT03388138)
Timeframe: Up to 1-Week Follow-up

Interventioneyes (Number)
Etafilcon A With Ketotifen0
Etafilcon A1

[back to top]

Monocular Contact Lens-corrected Distance Visual Acuity (Modified Intent-to-Treat Population)

Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit. (NCT03388138)
Timeframe: Baseline (Visit 1) and 1-week follow up (Visit 2)

,
InterventionlogMAR (Mean)
Visit 1 (Baseline)Visit 2 (1-week follow up)
Etafilcon A-0.110-0.117
Etafilcon A With Ketotifen-0.109-0.115

[back to top]

Monocular Contact Lens-corrected Distance Visual Acuity (Per-Protocol Population)

Monocular contact lens-corrected distance visual acuity was assessed using a logMAR visual acuity scale. This was evaluated for each eye, under high luminance and high contrast conditions at 4 meters from ETDRS charts. Distance visual acuity was reported by lens type and visit. (NCT03388138)
Timeframe: Baseline (Visit 1) and 1-week follow up (Visit 2)

,
InterventionlogMAR (Mean)
Visit 1 (Baseline)Visit 2 (1-week follow up)
Etafilcon A-0.109-0.118
Etafilcon A With Ketotifen-0.111-0.115

[back to top]

The Number of Eyes With Clinically Significant Slit Lamp Findings

Slit lamp findings were assessed using a biomicroscope for each subject eye at all scheduled and unscheduled visits. Clinical significant slit lamp findings are defined as Grade 3 or Grade 4. (Grade 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate and Grade 4= Severe). The data was dichotomized as 1=Grade 3 or Grade 4 and 0, otherwise. The number of eyes with clinically significant slit lamp findings for each lens type was reported. (NCT03388138)
Timeframe: Up to 1-Week Follow-up

InterventionNumber of Eyes (Number)
Etafilcon A With Ketotifen0
Etafilcon A0

[back to top]

Ocular Itching

The primary efficacy measure was ocular itching evaluated by the subject at 3 (± 1), 5 (±1), and 7 (± 1) minutes post-CAC (Conjunctival Allergen Challenge) at Visits 4b and 5, using a 0 to 4 Ora Calibra scale (0 = None , 4= An incapacitating itch with an irresistible urge to rub). (NCT03479307)
Timeframe: The outcome measure was assessed at Visit 4b (Day 1: 16h post-treatment) and Visit 5 (Day 8 ±3, 15 minutes post-treatment).

,,
Interventionunits on a scale (Mean)
Visit 4b: 3 minutes Post- CACVisit 4b: 5 minutes Post- CACVisit 4b: 7 minutes Post- CACVisit 5: 3 minutes Post- CACVisit 5: 5 minutes Post- CACVisit 5: 7 minutes Post- CAC
Bilastine Ophthalmic Solution 0.6%1.6091.7501.7470.6690.8280.826
Ketotifen Ophthalmic Solution 0.025% (Zaditen)1.8861.9191.8940.6580.9020.981
Vehicle of Bilastine Ophthalmic Solution2.2192.4902.5261.8402.0111.931

[back to top]